Threshold Pharmaceuticals Reports Third Quarter 2008 Financial Results
06. November 2008 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 6, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the third quarter ended September 30, 2008. The net loss for...
Threshold to Present At Rodman & Renshaw Healthcare Conference
05. November 2008 16:05 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 5, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it will present at the Rodman & Renshaw 10th Annual Healthcare Conference...
Threshold Pharmaceuticals Presents Encouraging Additional Preliminary Findings From a Phase 1 Clinical Trial of TH-302 for Solid Tumors
22. Oktober 2008 16:05 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Oct. 22, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced two presentations on its clinical stage hypoxia-activated prodrug, TH-302. The...
Threshold Pharmaceuticals Provides Clarification on Common Shares Outstanding Following Recent Private Placement
13. Oktober 2008 08:59 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Oct. 13, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) announced today a clarification for shareholders regarding the current number of common shares...
Threshold Pharmaceuticals Initiates a Clinical Trial Evaluating TH-302 in Patients With Soft Tissue Sarcoma
16. September 2008 08:25 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 16, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLDD), today announced that it has initiated a Phase 1/2 clinical trial of TH-302 in combination with...
Threshold Pharmaceuticals Achieves Compliance With NASDAQ Minimum Bid Price Rule
09. September 2008 08:25 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 9, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLDD), announced today that it has received written communication from the NASDAQ Listing...
Threshold Pharmaceuticals Completes $18 Million Private Equity Financing
02. September 2008 08:25 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 2, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLDD), today announced that its previously announced private placement of Threshold common stock and...
Threshold Pharmaceuticals Announces Reverse Stock Split
20. August 2008 08:25 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 20, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLDD) today announced the effectiveness of a reverse stock split. Effective today, every six shares of...
Threshold Pharmaceuticals Initiates a Second Clinical Trial Evaluating TH-302 in Patients With Solid Tumors
12. August 2008 08:25 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 12, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it has initiated a clinical trial of TH-302 in combination with various...
Threshold Pharmaceuticals Reports Second Quarter 2008 Financial Results
07. August 2008 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 7, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the second quarter ended June 30, 2008.
The net loss for the...